Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The current state of imaging biomarker development and evaluation
3
Zitationen
2
Autoren
2025
Jahr
Abstract
With a focus on imaging, this narrative review describes why biomarker research rarely culminates in anything clinically useful. We explain the difference between diagnostic and prognostic biomarkers and the different phases of their research. We describe what factors need consideration when designing research studies to generate evidence sufficient to translate a potential imaging biomarker into clinical practice. We emphasize the need to balance the number of biomarkers investigated with the number of available patient events, so that studies are not overwhelmed by false-positive results. We explain the need for rigorous evaluation, so that clinicians can be convinced the biomarker will work in their practice and benefit their patients. In particular, we explain why novel biomarkers should be evaluated alongside factors already known to be clinically useful, so that their incremental benefit, if any, can be determined.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 28.817 Zit.
TNM Classification of Malignant Tumours
1987 · 16.123 Zit.
A survey on deep learning in medical image analysis
2017 · 13.514 Zit.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.745 Zit.
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
2010 · 9.103 Zit.